XML 59 R48.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) $ / shares in Units, $ in Millions |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 36 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Mar. 18, 2024 USD ($) $ / shares | Feb. 26, 2024 USD ($) $ / shares | Jan. 23, 2024 USD ($) right $ / shares | Feb. 28, 2023 USD ($) | Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2023 | Dec. 31, 2026
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Business combination, contingent value, number of rights received | right |  |  | 1 |  |  |  |  |
Nimbus Therapeutics |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Upfront payments |  |  |  | $ 4,000 |  |  |  |
Keytruda royalties |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Percentage of net sales payable to alliance partner |  |  |  |  |  |  | 6.50% |
Keytruda royalties | Forecast |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Percentage of net sales payable to alliance partner |  |  |  |  |  |  |  | 2.50%
Keytruda royalties | Forecast | Bristol-Myers Squibb |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Payment and royalty allocation |  |  |  |  |  |  |  | 75.00%
Keytruda royalties | Forecast | Ono |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Payment and royalty allocation |  |  |  |  |  |  |  | 25.00%
Nimbus Therapuetics TYK2 Inhibitor |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Contingent sales-based milestones |  |  |  | $ 2,000 |  |  |  |
Other |  |  |  |  |  | $ 400 |  |
Nimbus Therapuetics TYK2 Inhibitor | Nimbus Therapeutics |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Change in control proceeds |  |  |  | 10.00% |  |  |  |
Percentage of ownership acquired |  |  |  | 100.00% |  |  |  |
RayzeBio |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Share price (in usd per share) | $ / shares |  | $ 62.50 |  |  |  |  |  |
Total consideration |  | $ 4,147 |  |  |  |  |  |
Business combination, consideration transferred |  | 3,600 |  |  |  |  |  |
Intangible assets |  | 3,700 |  |  |  |  |  |
RayzeBio | IPRD |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Business combination, recognized identifiable assets acquired and liabilities assumed, indefinite-lived intangible assets |  | 1,700 |  |  |  |  |  |
RayzeBio | R&D technology |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Business combination, recognized identifiable assets acquired and liabilities assumed, indefinite-lived intangible assets |  | 2,000 |  |  |  |  |  |
RayzeBio | Unvested Equity Awards |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Total consideration |  | 274 |  |  |  |  |  |
Mirati Therapeutics |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Share price (in usd per share) | $ / shares |  |  | $ 58.00 |  |  |  |  |
Total consideration |  |  | $ 4,801 |  |  |  |  |
Business combination, consideration transferred |  | 3,500 | $ 4,100 |  |  |  |  |
Business combination, contingent value, share price (in dollars per share) | $ / shares |  |  | $ 12.00 |  |  |  |  |
Continent consideration liability |  |  | $ 1,000 |  |  |  |  |
Business combination, contingent value payout, period |  |  | 7 years |  |  |  |  |
Intangible assets |  |  | $ 4,225 |  |  |  |  |
Inventories |  |  | 215 |  |  |  |  |
Mirati Therapeutics | Acquired marketed product rights |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Intangible assets |  | $ 640 |  |  |  |  |  |
Mirati Therapeutics | Unvested Equity Awards |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Total consideration |  |  | $ 114 |  |  |  |  |
Inventory Purchase Price Fair Value Adjustment |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Inventories |  |  |  |  | $ 148 |  |  |
Karuna |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Asset acquisition, share price (in dollars per share) | $ / shares | $ 330.00 |  |  |  |  |  |  |
Payments for asset acquisitions | $ 14,027 |  |  |  |  |  |  |
Payments for asset acquisitions, net of cash acquired | 12,900 |  |  |  |  |  |  |
Karuna | Vested Equity Awards |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Payments for asset acquisitions | 1,100 |  |  |  |  |  |  |
Karuna | Unvested Equity Awards |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Payments for asset acquisitions | $ 289 |  |  |  |  |  |  |
Karuna | Acquired IPRD |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |
Payments for asset acquisitions |  |  |  |  | $ 12,100 |  |  |

X
- Definition Asset Acquisition, Percentage of Ownership Acquired + References No definition available. + Details
Name: | bmy_AssetAcquisitionPercentageOfOwnershipAcquired
Namespace Prefix: | bmy_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Asset Acquisition, Share Price + References No definition available. + Details
Name: | bmy_AssetAcquisitionSharePrice
Namespace Prefix: | bmy_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Number Of Rights Received Per Share + References No definition available. + Details
Name: | bmy_BusinessCombinationContingentValueNumberOfRightsReceived
Namespace Prefix: | bmy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Contingent Value Payout, Period + References No definition available. + Details
Name: | bmy_BusinessCombinationContingentValuePayoutPeriod
Namespace Prefix: | bmy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Contingent Value, Share Price + References No definition available. + Details
Name: | bmy_BusinessCombinationContingentValueSharePrice
Namespace Prefix: | bmy_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement Contingent Payments Maximum Exposure + References No definition available. + Details
Name: | bmy_CollaborativeArrangementContingentPaymentsMaximumExposure
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License and Other Arrangements Upfront Payments + References No definition available. + Details
Name: | bmy_LicenseAndOtherArrangementsUpfrontPayments
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Licensing Arrangements + References No definition available. + Details
Name: | bmy_LicensingArrangementsLineItems
Namespace Prefix: | bmy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment And Royalty Allocation + References No definition available. + Details
Name: | bmy_PaymentAndRoyaltyAllocation
Namespace Prefix: | bmy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments For Asset Acquisitions + References No definition available. + Details
Name: | bmy_PaymentsForAssetAcquisitions
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments for Asset Acquisitions, Net Of Cash Acquired + References No definition available. + Details
Name: | bmy_PaymentsForAssetAcquisitionsNetOfCashAcquired
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage Of Net Sales Payable To Alliance Partner + References No definition available. + Details
Name: | bmy_PercentageOfNetSalesPayableToAlliancePartner
Namespace Prefix: | bmy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Settlement, Contingent Development, Change In Control Proceeds + References No definition available. + Details
Name: | bmy_SettlementContingentDevelopmentChangeInControlProceeds
Namespace Prefix: | bmy_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of inventory recognized as of the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of income related to nonoperating activities, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_OtherNonoperatingIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_NimbusTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bmy_LicensingAndOtherArrangementsAxis=bmy_KeytrudaRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_OnoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bmy_LicensingAndOtherArrangementsAxis=bmy_NimbusTherapueticsTYK2InhibitorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmy_RayzeBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=bmy_UnvestedEquityAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmy_MiratiTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmy_AcquiredMarketedProductRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmy_InventoryPurchasePriceFairValueAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=bmy_KarunaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=bmy_VestedEquityAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=bmy_AcquiredIPRDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |